Jim Cramer Says Sell Allergan Shares on Deal With Valeant

TheStreet's Jim Cramer says Herb Greenberg has convinced him that the problem with Valeant Pharmaceuticals is that the company must make deal after deal to keep going. Cramer says it is interesting to see shares of Allergan drop substantially for the first time and it tells him that this is not a cut-and-dry deal yet. Valeant's sale of the rights to some key drugs it got when it acquired Medicis Pharmaceuticals to Nestle all rely on this deal being completed. Cramer reminds investors to not forget that Valeant just bought Medicis a few years ago, and Cramer says the deal intrigues him enough to sell shares of Allergan.